229 related articles for article (PubMed ID: 22608344)
41. Successful intra-arterial thrombolysis in a patient with an intracranial meningioma.
Baiense RF; Abrahão A; Ricarte IF; Fukuda TG; Oliveira RA; Silva GS; Costa M; Teixeira MJ
J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e658-60. PubMed ID: 23830958
[TBL] [Abstract][Full Text] [Related]
42. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Garwood CL; Hwang JM; Moser LR
Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
[TBL] [Abstract][Full Text] [Related]
43. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
Wychowski MK; Kouides PA
Ann Pharmacother; 2012 Apr; 46(4):e10. PubMed ID: 22496474
[TBL] [Abstract][Full Text] [Related]
44. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
45. Intravenous recombinant tissue plasminogen activator thrombolysis in acute ischemic stroke due to middle cerebral artery dissection.
Doijiri R; Yokota C; Suzuki R; Toyoda K; Minematsu K
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):915.e7-9. PubMed ID: 22425201
[TBL] [Abstract][Full Text] [Related]
46. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
47. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
[TBL] [Abstract][Full Text] [Related]
48. Rash associated with dabigatran etexilate.
To K; Reynolds C; Spinler SA
Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
[TBL] [Abstract][Full Text] [Related]
49. Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Garber ST; Sivakumar W; Schmidt RH
J Neurosurg; 2012 May; 116(5):1093-6. PubMed ID: 22394293
[TBL] [Abstract][Full Text] [Related]
50. Anterior communicating artery aneurysm rupture after intravenous thrombolysis for acute middle cerebral artery thromboembolism: case report.
Rammos SK; Neils DM; Fraser K; Klopfenstein JD
Neurosurgery; 2012 Jun; 70(6):E1603-7; discussion E1607. PubMed ID: 21796012
[TBL] [Abstract][Full Text] [Related]
51. Endovascular therapy after stroke in a patient treated with dabigatran.
Moey AW; Koblar SA; Chryssidis S; Robinson M; Jannes J
Med J Aust; 2012 Apr; 196(7):469-71. PubMed ID: 22509880
[No Abstract] [Full Text] [Related]
52. The use of dabigatran immediately after atrial fibrillation ablation.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):264-8. PubMed ID: 21955008
[TBL] [Abstract][Full Text] [Related]
53. Risk factors and consequences of atrial fibrillation with rapid ventricular response in patients with ischemic stroke treated with intravenous thrombolysis.
Seet RC; Zhang Y; Rabinstein AA; Wijdicks EF
J Stroke Cerebrovasc Dis; 2013 Feb; 22(2):161-5. PubMed ID: 21855367
[TBL] [Abstract][Full Text] [Related]
54. Successful intravenous thrombolysis in a stroke patient with hemiballism.
Zidverc-Trajković J; Jovanović DR; Marjanović I; Radojičić A; Beslać-Bumbaširević L
Neurologist; 2011 Jul; 17(4):205-7. PubMed ID: 21712665
[TBL] [Abstract][Full Text] [Related]
55. [Atrial fibrillation: what the GP needs to know].
Diener HC; Kaeufer T; Bode C
MMW Fortschr Med; 2011 Sep; 153(38):44-7; quiz 48. PubMed ID: 21977796
[No Abstract] [Full Text] [Related]
56. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
Ohtani T; Sintoku R; Yajima T; Kaneko N
J Med Case Rep; 2019 Dec; 13(1):390. PubMed ID: 31875786
[TBL] [Abstract][Full Text] [Related]
57. Multimodality MRI and MRA for decision making in minor stroke: a case with internal carotid and distal middle cerebral artery occlusion.
Beitzke M; Enzinger C; Beitzke D; Niederkorn K; Offenbacher H; Niederkorn-Duft M; Fazekas F
J Neuroimaging; 2011 Apr; 21(2):e156-8. PubMed ID: 20572908
[TBL] [Abstract][Full Text] [Related]
58. Stroke and cardiac papillary fibroelastoma: mechanical thrombectomy after thrombolytic therapy.
Santos AF; Pinho J; Ramos V; Pardal J; Rocha J; Ferreira C
J Stroke Cerebrovasc Dis; 2014; 23(5):1262-4. PubMed ID: 24144594
[TBL] [Abstract][Full Text] [Related]
59. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
60. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
